Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP21A2 | P08686 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16396741 | 0.86 | CFD (0.46) | CYP17A1CYP11B1CYP21A2PTGER1SCD | |
| SCHEMBL16396742 | 0.86 | CFD (0.46) | CYP17A1CYP11B1CYP21A2PTGER1SCD | |
| SCHEMBL16410272 | 0.83 | HDAC3 (0.33) | CYP17A1CYP11B1CYP21A2ABCB1MTNR1A | |
| SCHEMBL16397377 | 0.80 | CFD (0.43) | PTGER1CYP2C9MTNR1AMTNR1BSLC1A5 | |
| SCHEMBL16397192 | 0.79 | MTNR1A (0.38) | PTGER1CYP2C9LMNAMTNR1AMTNR1B | |
| SCHEMBL16410429 | 0.78 | MEN1 (0.43) | PTGER1CYP2C9MTNR1AMTNR1BPOLB | |
| SCHEMBL16396476 | 0.77 | MTNR1A (0.40) | PTGER1CYP2C9MTNR1AMTNR1BSLC1A5 | |
| SCHEMBL16396881 | 0.77 | MTNR1A (0.40) | PTGER1CYP2C9ABCB1MTNR1AMTNR1B | |
| SCHEMBL16396265 | 0.77 | MTNR1A (0.40) | PTGER1CYP2C9ABCB1SGMS2MTNR1A | |
| SCHEMBL16397748 | 0.77 | CFD (0.38) | PTGER1CYP2C9ABCB1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CYP17A1 492/4885CYP11B1 582/4885CYP21A2 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.